Phase 1 N=46 A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Maximum Tolerated Dose (MTD): Part 1 — 10.0 milligram/kilogram (mg/kg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=13 Metazym for the Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD)
Metachromatic Leukodystrophy (MLD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 4; 5; 4 participants
Phase 4 N=51 Comparison of Oral Zaldiar With Intravenous Paracetamol and Tramadol
Pain
Primary: Acute Pain — 1.5; 1.74 units on a scale
Phase 2 N=110 BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Ovarian Neoplasms
Primary: Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1 — 30.6; 43.1 percentage of participants
Phase 2 N=204 Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
Upper Gastrointestinal Mucosal Damage
Primary: Incidence of Subjects With Gastroduodenal Erosions and Ulcers. — 72; 54; 19; 36 participants
Phase 3 N=451 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Bronchopulmonary Dysplasia
Primary: Survival Without BPD at 36 Weeks — 80; 70; 149; 152 participants — p=0.427
Phase 3 N=247 Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
IDIOPATHIC PARKINSON'S DISEASE
Primary: Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts…
Phase 2 N=60 Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Lymphoma
Primary: Progression — 22; 1 participants — p=0.51
Phase 2 N=66 Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement
Osteoarthritis
Primary: Change From Baseline in Isometric Quadriceps Muscle Torque 3.5 Weeks Post-operatively — -0.40; -0.67 change in N-m/kg — p=<0.001
Phase 2 N=35 Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Brain and Central Nervous System Tumors
Primary: Maximum Tolerated Dose (Phase I) — 1700; 1700; 1700 mg/day x 5 days
Phase 2 N=167 MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Anti-tumor Response Defined as Either a CR, PR, or SD as Defined by RECIST — 1; 8; 6 participants
N/A N=132 DW Evaluation of Lotrafilcon B Lenses in a Modified Design
Myopia
Primary: Proportion of Subjects Satisfying the 'no Re-fit' Criteria in Both Eyes — 100.0; 100.0; 100.0; 100.0 percentage of subjects
N/A N=37 Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Constipation-predominant Irritable Bowel Syndrome
Primary: Severity of Constipation in Each Arm at Week 1 After Completion of Therapy — 61.2; 28.6 units on a scale
N/A N=54 Behavioral Change in the Mother-Infant Dyad: Preventing Postpartum Depression
Postpartum Depression
Primary: Hamilton Rating Scales of Depression — 12.09; 17.17 units on a scale — p=.01
Phase 2 N=39 Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib
Gastrointestinal Stromal Tumors
Primary: Antitumor Activity of Dovitinib in Terms of Disease Control Rate (DCR): Complete Response+Partial Response +Stable Disease — 52.6 Percentage of Participants